Authors: Bordin, F., Terriaca, G., Apostolico, A. et al
Source: Cell Death Discovery 10, 498 (2024)
We are thrilled to share insights from a study entitled "SMURF1 and SMURF2 directly target GLI1 for ubiquitination and proteasome-dependent degradation" published in Cell Death Discovery by Bordin, F., Terriaca, G., Apostolico, A. et al
"The transcription factor GLI1 is the main and final effector of the Hedgehog signaling pathway, which is involved in embryonic development, cell proliferation and stemness. Whether activated through canonical or non-canonical mechanisms, GLI1 aberrant activity is associated with Hedgehog-dependent cancers, including medulloblastoma, as well as other tumoral contexts. Notwithstanding a growing body of evidence, which have highlighted the potential role of post translational modifications of GLI1, the complex mechanisms modulating GLI1 stability and activity have not been fully elucidated. Here, we present a novel role played by SMURF1 and SMURF2 in the suppression of the Hedgehog/GLI signaling pathway through a direct targeting of GLI1. Indeed, the two SMURFs can interact with GLI1, exploiting the proline rich regions present on GLI1 protein, and trigger its polyubiquitination and proteasomal degradation, leading to a suppression of the Hedgehog pathway activity and a reduction of Hh-dependent tumor cell proliferation. Overall, this study adds new relevance to a tumor suppressive role of SMURFs on the Hedgehog pathway and confers upon them the status of potential therapeutic tools, either in canonical or non-canonical Hedgehog pathway aberrant activation."
Congratulations to all authors for this great article.
Our DreamFect Gold was used to transfect DNA in HEK293T cells.
Read the article See our DreamFect Gold
Related publications
TRACERx analysis identifies a role for FAT1 in regulating chromosomal
Phenotypic profiling of solute carriers characterizes serine transport in cancer
